BSOP prescriber information

A structured behavioural support programme for patients prescribed tirzepatide (Mounjaro®), delivered alongside medication as required by NICE TA1026 and MHRA guidance. 

Key areas include: 

• Integrating medication with behavioural change, to support long-term weight management.
• Nutritional guidance focused on appetite regulation, balanced eating, and sustainable meal planning.
• Physical activity support, including resistance training and movement adaptations for those with limited mobility.
• Sleep and stress management to address common barriers to weight loss and overall wellbeing.
• Goal setting that includes both weight-related and non-scale outcomes for a holistic view of progress.

Eligibility confirmation remains the responsibility of the prescriber; Xyla does not verify eligibility 

• Aged over 18​ 

• BMI of at least 40 kg/m2 ​
  (reduced to 37.5 kg/m2 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds)​ 

• 4 or more of the following comorbidities:​ 

• Dyslipidemia​ 

• Hypertension​ 

• Cardiovascular disease​ 

• Obstructive sleep apnoea​ 

• Type 2 Diabetes  

Exclusion Criteria  

• Aged under 18​ 

• Pregnant or planning to become pregnant in the next month​ 

• Currently breastfeeding​ 

• Active eating disorder​ 

• Hypersensitivity or intolerance to tirzepatide​ 

• Contraindicated by BNF cautions, medication interactions and local criteria 

Service Users are to be offered an informed choice between 3 delivery channels.  

1. Remote group sessions; BSOP tailored live, interactive sessions via MS teams led by a trained health coach   
2. Digital Programme – BSOP tailored, personalised guidance through an easy-to-use app, delivered by our digital Partner Oviva  
3. In person face to face group sessions- Participants opting for face-to-face sessions may be placed in existing DPP groups, which include individuals not on weight-loss medication. These groups focus on type 2 diabetes prevention and may not fully align with BSOP objectives. 

The purpose of the BSOP programme is to provide comprehensive, practical, and person-centred support to patients embarking on weight loss journeys with pharmacological assistance. Its purpose is to:  

Enable sustainable behaviours for long-term improvements in metabolic health, physical wellbeing, and lifestyle. 

• Support balanced macro and micronutrient dietary habits.
• Equip patients with tools for informed choices around physical activity, food, self-care, and emotional health.
• Foster understanding of nutrition’s role in muscle retention, metabolic function, and body composition.
• Offer tailored strategies acknowledging obesity as a chronic, relapsing condition.
• Promote health literacy, self-efficacy, and non-stigmatising engagement with health services.
• Establish accessible, non-clinical support structures alongside prescribing pathways.

Onboarding  

How long will someone need to wait to access the programme?  

• Contact initiated within 5 operational days via email and SMS. 

• If no response, follow-up via phone and letter within one calendar month.
• After three unsuccessful contact attempts, the individual will be discharged.
• Prescribers are encouraged to refer to BSOP at the time of prescribing tirzepatide to minimise delays.

Prescriber Service User Programme updates    

Reporting will mirror that of the NHS DPP programme. Information will be shared at the following points;   

• Referral Received  
• Programme Start   
• Not Started- Discharged 
• Not Completed- Discharged 
• Completed 

 This information will be sent to the contacts we currently have on file for the NHS DPP. If you need any contacts adding, please do let us know. Please be aware that this contact list will be used for both NDPP and BSOP.  

Discharge occurs when: 

• No contact after three attempts over one calendar month. 

• Three consecutive uninformed missed sessions (F2F or Remote). 

• No activity for three months (Digital). 

• No response to re-engagement efforts. 

• Remote groups available in Urdu, Bengali, and Gujarati via NHS DPP platform. Service users joining language-specific groups will be informed that these are part of the existing DPP programme and may differ from BSOP objectives. 

• BSOP-specific language groups may be developed based on demand 

• Digital Programme- Oviva supports multiple languages via multilingual staff and translation services. 

• Oviva app is currently available only in English; telephone-based support is available with translation assistance. 

Clinical responsibility remains with the prescriber. 

• Patients follow a titration schedule with healthcare appointments.
• Safeguarding concerns are raised as appropriate.

Service users can only re-start the programme if re-referred 

• Discontinuation of tirzepatide: Users may continue BSOP.
• Pregnancy: Users may continue BSOP with tailored support per NICE Guideline NG247.

ICBs are operating different referral pathways for both the prescription of Tirzepatide and the BSOP Programme. The referral pathway will have been communicated by your ICB. Please contact BSOPenquires@xylaservices.com for any additional support if needed.